Chronic immune thrombocytopenic purpura in children overview of 60 patients
Background: A small percentage of children with Immune thrombocytopenic purpura (ITP) suffer from a clinically significant disease with severe thrombocytopenia that requires intervention. Treatment for these children presents a challenge as there are few known therapies that offer long-term remissio...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-05-01
|
Series: | Pediatric Hematology Oncology Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468124516300079 |
id |
doaj-151d2fbb35b64eb7bc41515da1615c3e |
---|---|
record_format |
Article |
spelling |
doaj-151d2fbb35b64eb7bc41515da1615c3e2020-11-24T23:17:55ZengElsevierPediatric Hematology Oncology Journal2468-12452016-05-011191210.1016/j.phoj.2016.04.002Chronic immune thrombocytopenic purpura in children overview of 60 patientsAhmed Hatem Sabhan0Mazin Faisal Al-Jadiry1Hasanein Habeeb Ghali2Wisam Majeed Abed3Salma Abbas Al-Hadad4Oncology Unit, Children's Welfare Teaching Hospital, Medical City, Baghdad, IraqOncology Unit, Department of Pediatrics, Children's Welfare Teaching Hospital, Baghdad College of Medicine, Medical City, Baghdad, IraqOncology Unit, Department of Pediatrics, Children's Welfare Teaching Hospital, Baghdad College of Medicine, Medical City, Baghdad, IraqOncology Unit, Children's Welfare Teaching Hospital, Medical City, Baghdad, IraqOncology Unit, Department of Pediatrics, Children's Welfare Teaching Hospital, Baghdad College of Medicine, Medical City, Baghdad, IraqBackground: A small percentage of children with Immune thrombocytopenic purpura (ITP) suffer from a clinically significant disease with severe thrombocytopenia that requires intervention. Treatment for these children presents a challenge as there are few known therapies that offer long-term remission, and all that are known have significant side effects and toxicities. Aim of the study: To evaluate the effects of a variety of treatment modalities on the clinical course, and long treatment outcomes in children with chronic ITP. Patients & methods: A study involved 60 children with chronic ITP who were referred to Hemato-Oncology unit/Children's Welfare Teaching Hospital/Medical City/Baghdad. Treatment of patients included steroid, Intravenous Immunoglobulins, Anti D immunoglobulin, 6-Mercaptopurine, Rituximab and splenectomy. The Period of data collection and analysis was from May 2009 to May 2011. Results: The most common presenting symptom was skin bleeding, seen in 42 (70%) patients. Thirty-four patients received one or more courses of steroids. Complete response was achieved in 7 (20.5%) patients while there was no response in 12 (35.2%) patients, Intravenous immunoglobulin was used for 5 patients, only one (16%) exhibited a good response. Anti D Immunoglobulin was used in six patients; only one (8.3%) patient got good response. Twelve patients received 6-mercaptopurine, only one (8.3%) patient had a partial response. Six patients received Rituximab; three (50%) had a partial response. Six patients underwent splenectomy; response was noted in 5/6 (83.3%) patients. At the end of the study; complete response was seen in 13 (22.4%) patients, partial in 19 (31.6%), no response in 28 (46.7%) patients. Conclusions: Splenectomy is the most effective treatment modality when treating children with chronic ITP whose symptoms are severe.http://www.sciencedirect.com/science/article/pii/S2468124516300079ITPChronicChildren |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ahmed Hatem Sabhan Mazin Faisal Al-Jadiry Hasanein Habeeb Ghali Wisam Majeed Abed Salma Abbas Al-Hadad |
spellingShingle |
Ahmed Hatem Sabhan Mazin Faisal Al-Jadiry Hasanein Habeeb Ghali Wisam Majeed Abed Salma Abbas Al-Hadad Chronic immune thrombocytopenic purpura in children overview of 60 patients Pediatric Hematology Oncology Journal ITP Chronic Children |
author_facet |
Ahmed Hatem Sabhan Mazin Faisal Al-Jadiry Hasanein Habeeb Ghali Wisam Majeed Abed Salma Abbas Al-Hadad |
author_sort |
Ahmed Hatem Sabhan |
title |
Chronic immune thrombocytopenic purpura in children overview of 60 patients |
title_short |
Chronic immune thrombocytopenic purpura in children overview of 60 patients |
title_full |
Chronic immune thrombocytopenic purpura in children overview of 60 patients |
title_fullStr |
Chronic immune thrombocytopenic purpura in children overview of 60 patients |
title_full_unstemmed |
Chronic immune thrombocytopenic purpura in children overview of 60 patients |
title_sort |
chronic immune thrombocytopenic purpura in children overview of 60 patients |
publisher |
Elsevier |
series |
Pediatric Hematology Oncology Journal |
issn |
2468-1245 |
publishDate |
2016-05-01 |
description |
Background: A small percentage of children with Immune thrombocytopenic purpura (ITP) suffer from a clinically significant disease with severe thrombocytopenia that requires intervention. Treatment for these children presents a challenge as there are few known therapies that offer long-term remission, and all that are known have significant side effects and toxicities.
Aim of the study: To evaluate the effects of a variety of treatment modalities on the clinical course, and long treatment outcomes in children with chronic ITP.
Patients & methods: A study involved 60 children with chronic ITP who were referred to Hemato-Oncology unit/Children's Welfare Teaching Hospital/Medical City/Baghdad. Treatment of patients included steroid, Intravenous Immunoglobulins, Anti D immunoglobulin, 6-Mercaptopurine, Rituximab and splenectomy. The Period of data collection and analysis was from May 2009 to May 2011.
Results: The most common presenting symptom was skin bleeding, seen in 42 (70%) patients. Thirty-four patients received one or more courses of steroids. Complete response was achieved in 7 (20.5%) patients while there was no response in 12 (35.2%) patients, Intravenous immunoglobulin was used for 5 patients, only one (16%) exhibited a good response. Anti D Immunoglobulin was used in six patients; only one (8.3%) patient got good response. Twelve patients received 6-mercaptopurine, only one (8.3%) patient had a partial response. Six patients received Rituximab; three (50%) had a partial response. Six patients underwent splenectomy; response was noted in 5/6 (83.3%) patients. At the end of the study; complete response was seen in 13 (22.4%) patients, partial in 19 (31.6%), no response in 28 (46.7%) patients.
Conclusions: Splenectomy is the most effective treatment modality when treating children with chronic ITP whose symptoms are severe. |
topic |
ITP Chronic Children |
url |
http://www.sciencedirect.com/science/article/pii/S2468124516300079 |
work_keys_str_mv |
AT ahmedhatemsabhan chronicimmunethrombocytopenicpurpurainchildrenoverviewof60patients AT mazinfaisalaljadiry chronicimmunethrombocytopenicpurpurainchildrenoverviewof60patients AT hasaneinhabeebghali chronicimmunethrombocytopenicpurpurainchildrenoverviewof60patients AT wisammajeedabed chronicimmunethrombocytopenicpurpurainchildrenoverviewof60patients AT salmaabbasalhadad chronicimmunethrombocytopenicpurpurainchildrenoverviewof60patients |
_version_ |
1725582663830470656 |